Focus: Pulse Biosciences develops nano-pulse stimulation devices and inhaled nitric oxide therapies across cardiovascular, metabolic, and oncology indications. The company operates as a focused medical device and biotech player with limited public disclosure on scale.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
Pulse Biosciences presents a niche opportunity for those seeking device-biotech hybrid experience, but limited hiring, opaque financials, and data quality red flags warrant caution before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Most advanced program with Phase 3 status in PAH and Phase 3 in pulmonary fibrosis; multiple dosing regimens in trial.
Help build intelligence for Pulse Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Pulse Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Diversified cardiac and dermatology ablation platform with multiple catheter configurations under investigation.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles